↓ Skip to main content

Shared decision making PLUS – a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS)

Overview of attention for article published in BMC Psychiatry, February 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
184 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Shared decision making PLUS – a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS)
Published in
BMC Psychiatry, February 2017
DOI 10.1186/s12888-017-1240-3
Pubmed ID
Authors

Johannes Hamann, Fabian Holzhüter, Lynne Stecher, Stephan Heres

Abstract

Shared decision making (SDM) is a model of how doctors and patients interact with each other. It aims at changing the traditional power asymmetry between doctors and patients by strengthening the exchange of information and the decisional position of the patient. Although SDM is generally welcomed by mental health patients as well as by mental health professionals its implementation in routine care, especially in the more acute settings, is still lacking. SDM-PLUS has been developed as an approach that addresses both patients and mental health professionals and aims at implementing SDM even for the very acutely ill patients. The SDM-PLUS study will be performed as a matched-pair cluster-randomized trial in acute psychiatric wards. On wards allocated to the intervention group personnel will receive communication training (addressing how to implement SDM for various scenarios) and patients will receive a group intervention addressing patient skills for SDM. Wards allocated to the control condition will continue treatment as usual. A total sample size of 276 patients suffering from schizophrenia or schizoaffective disorder on 12 wards is planned. The main outcome parameter will be patients' perceived involvement in decision making during the inpatient stay measured with the SDM-Q-9 questionnaire. Secondary objectives include the therapeutic relationship and long term outcomes such as medication adherence and rehospitalization rates. In addition, process measures and qualitative data will be obtained to allow for the analysis of potential barriers and facilitators of SDM-PLUS. The primary analysis will be a comparison of SDM-Q-9 sum scores 3 weeks after study inclusion (or discharge, if earlier) between the intervention and control groups. To assess the effect of the intervention on this continuous primary outcome, a random effects linear regression model will be fitted with ward (cluster) as a random effect term and intervention group as a fixed effect. This will be the first trial examining the SDM-PLUS approach for patients with schizophrenia or schizoaffective disorder in very acute mental health inpatient settings. Within the trial a complex intervention will be implemented that addresses both patients and health care staff to yield maximum effects. German Clinical Trials Register DRKS00010880 . Registered 09 August 2016.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 184 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 183 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 15%
Student > Bachelor 22 12%
Researcher 19 10%
Student > Doctoral Student 15 8%
Student > Postgraduate 15 8%
Other 33 18%
Unknown 53 29%
Readers by discipline Count As %
Medicine and Dentistry 38 21%
Nursing and Health Professions 35 19%
Psychology 28 15%
Biochemistry, Genetics and Molecular Biology 4 2%
Social Sciences 3 2%
Other 12 7%
Unknown 64 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2017.
All research outputs
#20,406,219
of 22,955,959 outputs
Outputs from BMC Psychiatry
#4,246
of 4,725 outputs
Outputs of similar age
#271,173
of 311,210 outputs
Outputs of similar age from BMC Psychiatry
#96
of 104 outputs
Altmetric has tracked 22,955,959 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,725 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,210 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.